文献速递消化道肿瘤放疗

2017年直肠癌阿西西智库会议:定位文件

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper.
PubMed 文献 · Radiother Oncol · 2019-08-17

该定位文件通过问卷调查欧洲专家委员会在T2、T3和T4直肠癌管理中的争议领域,将治疗选项一致性低于70%定义为「灰色地带」,会议识别了这些不确定区域并提出了针对早期、中期和晚期直肠癌的临床试验建议。

要点

  • 一致性低于70%的治疗选项被定义为不确定性「灰色地带」。
  • 争议集中在cT2-3a中低位直肠癌的新辅助治疗与器官保留。
  • 会议针对早期、中期和晚期直肠癌提出了临床试验建议。

核心结论

  • 会议成功识别了直肠癌管理中的「灰色地带」,并根据新证据提出了针对早期、中期和晚期直肠癌治疗的临床试验。

研究设计与样本

  • 通过问卷调查欧洲直肠癌阿西西智库会议专家委员会,调查T2、T3和T4直肠癌管理中的争议领域。
  • 治疗选项一致性低于70%被定义为不确定性并选为「灰色地带」。
  • 分歧较大的主题由工作组选为会议讨论内容。

主要发现

  • cT2-cT3-cT4中识别的争议临床问题需要进一步研究。
  • 讨论聚焦于cT2-3a中低位直肠癌的新辅助治疗和器官保留的作用。
  • 讨论聚焦于无高危特征的cT3低位直肠癌的新辅助治疗。
  • 讨论聚焦于T4肿瘤的全新辅助治疗、放疗推量及最佳放化疗方案。

关键数值与推荐

  • 治疗选项一致性低于70%被定义为不确定性「灰色地带」。

临床怎么用

  • 临床可参考会议识别的「灰色地带」及提出的临床试验方向,针对早期、中期和晚期直肠癌的新辅助治疗、器官保留和放化疗方案进行决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSES: To describe current practice in the management of rectal cancer, to identify uncertainties that usually arise in the multidisciplinary team (MDT)'s discussions ('grey zones') and propose next generation studies which may provide answers to them. MATERIALS AND METHODS: A questionnaire on the areas of controversy in managing T2, T3 and T4 rectal cancer was drawn up and distributed to the Rectal-Assisi Think Tank Meeting (ATTM) Expert European Board. Less than 70% agreement on a treatment option was indicated as uncertainty and selected as a 'grey zone'. Topics with large disagreement were selected by the task force group for discussion at the Rectal-ATTM. RESULTS: The controversial clinical issues that had been identified within cT2-cT3-cT4 needed further investigation. The discussions focused on the role of (1) neoadjuvant therapy and organ preservation on cT2-3a low-middle rectal cancer; (2) neoadjuvant therapy in cT3 low rectal cancer without high risk features; (3) total neoadjuvant therapy, radiotherapy boost and the best chemo-radiotherapy schedule in T4 tumors. A description of each area of investigation and trial proposals are reported. CONCLUSION: The meeting successfully identified 'grey zones' and, in the light of new evidence, proposed clinical trials for treatment of early, intermediate and advanced stage rectal cancer.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Valentini V, Marijnen C, Beets G, et al. The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. Radiother Oncol. 2019. PMID: 31431374. doi:10.1016/j.radonc.2019.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。